Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cladribine retreatment versus switch in relapsing-remitting multiple sclerosis
ACTRN12619000257167Phase 4Active, not recruiting
- Sponsor
- John Hunter Hospital
- Start
- Mar 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of cladribine in multiple sclerosis (MS) (4 arms), sponsored by John Hunter Hospital. Primary endpoint: Treatment response by NEDA3 over 6 years. Started Mar 2019; status: active, not recruiting.
02
Drugs
cladribine
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on ACTRN12619000257167.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12619000257167.